Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GI14-198

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients

Status: Open to Accrual

This is a phase II, multicenter, double-blinded, randomized, 2-arm trial evaluating the efficacy and safety of mFOLFIRINOX plus ramucirumab (Arm A) vs. mFOLFIRINOX plus placebo (Arm B) in up to 95 subjects with advanced pancreatic cancer not amenable to curative treatment. Subjects will be randomized in a 1:1 ratio. Subjects on both arms will continue treatment until disease progression or unacceptable toxicity. Each cycle will be 28 days.

  • Condition: Pancreatic cancer
  • Intervention:
    • Drug: mFOLFIRINOX
    • Drug: Ramucirumab
    • Other: Placebo
  • Phase: Phase II

For full description, see www.clinicaltrials.gov. (Study #NCT02581215).

Read a news release about this trial.

Project Manager: Donna Sullivan, dsullivan@hoosiercancer.org; (317) 634-5842, ext. 40.